Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis
Tumor tropism of human bone marrow-derived mesenchymal stem cells (MSC) has been
exploited for the delivery of therapeutic genes for anticancer therapy. However, the exact …
exploited for the delivery of therapeutic genes for anticancer therapy. However, the exact …
Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma
Human mesenchymal stem cells (MSCs) have increasingly been used as cellular vectors
for the delivery of therapeutic genes to tumors. However, the precise mechanism of …
for the delivery of therapeutic genes to tumors. However, the precise mechanism of …
Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP5+, Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma …
…, CM Guo, KM Hui, I Batinic-Haberle, PYP Lam - Stem cell reviews and …, 2016 - Springer
Glioblastoma multiforme is the most malignant tumor of the brain and is challenging to treat
due to its highly invasive nature and heterogeneity. Malignant brain tumor displays high …
due to its highly invasive nature and heterogeneity. Malignant brain tumor displays high …
[HTML][HTML] Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling
…, KH Lim, HS Leong, NG Iyer, KM Hui, PYP Lam - Molecular Therapy, 2015 - cell.com
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the
world. The multikinase inhibitor sorafenib only demonstrated marginal improvement in overall …
world. The multikinase inhibitor sorafenib only demonstrated marginal improvement in overall …
[HTML][HTML] Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme
The interleukin-13 receptor alpha2 (IL-13Rα2) is a cancer-associated receptor overexpressed
in human glioblastoma multiforme (GBM). This receptor is undetectable in normal brain …
in human glioblastoma multiforme (GBM). This receptor is undetectable in normal brain …
The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain
PYP Lam, JE Sublett, AD Hollenbach… - Molecular and cellular …, 1999 - Am Soc Microbiol
The chimeric transcription factor Pax3-FKHR, produced by the t (2; 13)(q35; q14) chromosomal
translocation in alveolar rhabdomyosarcoma, consists of the two Pax3 DNA binding …
translocation in alveolar rhabdomyosarcoma, consists of the two Pax3 DNA binding …
Potential of gene therapy for brain tumors
PYP Lam, XO Breakefield - Human molecular genetics, 2001 - academic.oup.com
Brain tumors comprise a broad spectrum of biological and clinical entities making it unlikely
for any single therapeutic approach to be universally applicable. In particular, malignant …
for any single therapeutic approach to be universally applicable. In particular, malignant …
[HTML][HTML] The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
J Yuan, WH Ng, PYP Lam, Y Wang, H Xia, J Yap… - Oncogene, 2018 - nature.com
Although extensively studied for three decades, the molecular mechanisms that regulate the
RAF/MEK/ERK kinase cascade remain ambiguous. Recent studies identified the …
RAF/MEK/ERK kinase cascade remain ambiguous. Recent studies identified the …
The molecular genetics of central nervous system tumors
HK Ng, PYP Lam - Pathology, 1998 - Taylor & Francis
Over the past few years, although much has been learned about the molecular genetics of
central nervous system (CNS) tumors, researchers and pathologists are only beginning to …
central nervous system (CNS) tumors, researchers and pathologists are only beginning to …
[HTML][HTML] Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
…, SH Lai, MMF Ho, N Dinesh, CK Tham, PYP Lam - BMC cancer, 2015 - Springer
Background The treatment of glioblastoma multiforme (GBM) is an unmet clinical need. The
5-year survival rate of patients with GBM is less than 3%. Temozolomide (TMZ) remains the …
5-year survival rate of patients with GBM is less than 3%. Temozolomide (TMZ) remains the …